Targeting invasive and angiogenic mechanisms in human glioblastoma
The goal of the project is to identify new targets for brain tumor treatment. We are currently validating interesting candidates experimentally. At this stage "brukermedvirkning" is not relevant, but might become relevant when/if we enter the clinical phase of development. There is still a long way to go as we first need to verify candidates and then proceed with a DOFI to BTO. Then we can start to attract investors for drug development or think about drug repurposing strategies.
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Neuro Oncol 2017 Oct 10. Epub 2017 okt 10
The angiogenic switch leads to a metabolic shift in human glioblastoma.
Neuro Oncol 2017 03 01;19(3):383-393.
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Neuro Oncol 2016 Dec;18(12):1644-1655. Epub 2016 jun 10